Highly Sensitive Noninvasive Cardiac Transplant Rejection Monitoring Using Targeted Quantification of Donor-Specific Cell-Free Deoxyribonucleic Acid

• Published in: Journal of the American College of Cardiology Vol. 63; no. 12; pp. 1224 - 1226
• Main Authors: Hidestrand, Mats, Tomita-Mitchell, Aoy, Hidestrand, Pip M., Oliphant, Arnold, Goetsch, Mary, Stamm, Karl, Liang, Huan-Ling, Castleberry, Chesney, Benson, D. Woodrow, Stendahl, Gail, Simpson, Pippa M., Berger, Stuart, Tweddell, James S., Zangwill, Steven, Mitchell, Michael E.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2014; Elsevier Limited
• Subjects: Binomial distribution; Biopsy; Cardiology; Cardiovascular; Deoxyribonucleic acid; DNA; DNA - blood; DNA - genetics; Genomes; Genotype; Graft Rejection - diagnosis; Graft Rejection - genetics; Heart; Heart Transplantation; Humans; Intubation; Laboratories; Medical imaging; Patients; Pediatrics; Predictive Value of Tests; Prospective Studies; Sensitivity and Specificity; Single-Blind Method; Surveillance; Tissue Donors; Transplants & implants
• ISSN: 0735-1097; 1558-3597; 1558-3597
• DOI: 10.1016/j.jacc.2013.09.029

Rejection from heart transplant recipients with biopsy- proven rejection (> The International Society for Heart and Lung Transplantation grade 2R or antibody mediated rejection 1) before initiation of treatment, during treatment, and at 1 week. The DScf-DNA was compared with other candidate noninvasive laboratory variables (B-natriuretic peptide, troponin, and C-reactive protein) as well as echocardiographically determined left ventricular ejection fraction in predicting rejection on biopsy; DScf-DNA had the highest sensitivity and specificity (100% and 84%, respectively).